



RESEARCH

Open Access

Dermal fibroblasts display similar phenotypic and differentiation capacity to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic potential

Antonella Blasi^{1†}, Carmela Martino^{1†}, Luigi Balducci¹, Marilisa Saldarelli¹, Antonio Soleti¹, Stefania E Navone², Laura Canzi², Silvia Cristini², Gloria Invernici², Eugenio A Parati², Giulio Alessandri^{2*}

Abstract

Background: Mesenchymal stem cells (MSCs) are multipotent stem cells able to differentiate into different cell lineages. However, MSCs represent a subpopulation of a more complex cell composition of stroma cells contained in mesenchymal tissue. Due to a lack of specific markers, it is difficult to distinguish MSCs from other more mature stromal cells such as fibroblasts, which, conversely, are abundant in mesenchymal tissue. In order to find more distinguishing features between MSCs and fibroblasts, we studied the phenotypic and functional features of human adipose-derived MSCs (AD-MSCs) side by side with normal human dermal fibroblasts (HNDFs) *in vitro*

Methods: AD-MSCs and HNDFs were cultured, expanded and phenotypically characterized by flow cytometry (FC). Immunofluorescence was used to investigate cell differentiation. ELISA assay was used to quantify angiogenic factors and chemokines release. Cultures of endothelial cells (ECs) and a monocyte cell line, U937, were used to test angiogenic and anti-inflammatory properties.

Results: Cultured AD-MSCs and HNDFs display similar morphological appearance, growth rate, and phenotypic profile. They both expressed typical mesenchymal markers-CD90, CD29, CD44, CD105 and to a minor extent, the adhesion molecules CD54, CD56, CD106 and CD166. They were negative for the stem cell markers CD34, CD146, CD133, CD117. Only aldehyde dehydrogenase (ALDH) was expressed. Neither AD-MSCs nor HNDFs differed in their multi-lineage differentiation capacity; they both differentiated into osteoblast, adipocyte, and also into cardiomyocyte-like cells. In contrast, AD-MSCs, but not HNDFs, displayed strong angiogenic and anti-inflammatory activity. AD-MSCs released significant amounts of VEGF, HGF and Angiopoietins and their conditioned medium (CM) stimulated ECs proliferation and tube formations. In addition, CM-derived AD-MSCs (AD-MSCs-CM) inhibited adhesion molecules expression on U937 and release of RANTES and MCP-1. Finally, after priming with TNF α , AD-MSCs enhanced their anti-inflammatory potential; while HNDFs acquired pro-inflammatory activity.

Conclusions: AD-MSCs cannot be distinguished from HNDFs *in vitro* by evaluating their phenotypic profile or differentiation potential, but only through the analysis of their anti-inflammatory and angiogenic properties. These results underline the importance of evaluating the angiogenic and anti-inflammatory features of MSCs preparation. Their priming with inflammatory cytokines prior to transplantation may improve their efficacy in cell-based therapies for tissue regeneration.

* Correspondence: cisiamo2@yahoo.com

† Contributed equally

²Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute "Carlo Besta", 20133 Milan, Italy
Full list of author information is available at the end of the article

Background

Within the panorama of adult stem cells, mesenchymal stem cells (MSCs) have been proposed for application in cell-based therapies because of their multipotential differentiation capacity, easy tissue accessibility and capacity for ex-vivo expansion [1]. MSCs are localized in the stroma of tissue or organs, and they have been isolated and characterized from different adult tissue sources such as bone marrow (BM), skeletal muscle, pancreas, vessels, dental pulp and adipose tissue [2-7]. Different methods for their isolation and culture expansion have been described [3,4,8]. The majority of techniques used direct adhesion to tissue culture plastic to separate MSCs from the unwanted cells contained in the stroma [5,8]. This procedure can be easily applied to separate MSCs from BM or umbilical cord blood. In fact, unwanted cells continue to float in the culture medium and can be easily discarded by replacing the culture medium. The technique to separate MSCs from non-hematopoietic tissue, for example adipose tissue, is more complex because MSCs are only a small cell subpopulation of the total stromal cells that adhere to plastic after seeding. In particular, fibroblasts are adherent proliferating cells which are difficult to remove because they can survive and grow even under extremely selective culture conditions.

Fibroblasts are considered mature mesenchymal cells that are particularly abundant in the connective of each organ and tissue. Therefore, these cells are the most frequent contaminating cell phenotype present in many cell culture systems [9]. Not only is it difficult to apply techniques which successfully eliminate fibroblasts from a culture, it is also particularly complex to distinguish MSCs from fibroblasts in the same culture. Fibroblasts and MSCs have an extremely similar morphological appearance [10]; they both proliferate well and have many identical cell surface markers [10]. MSCs lack a specific surface antigen that precisely differentiates these cells from fibroblasts. Stro-1, and more recently CD146, have been claimed as specific markers for MSCs [11-13]. However, these markers seem limited to MSCs derived from BM (BM-MSCs) or from renal tissue, since adipose-derived MSCs (AD-MSCs), for example, did not display these markers [14,15]. In spite of these differences, MSCs of different tissue origin possess a very similar phenotypic profile. They usually express high levels of mesenchymal markers and in general do not express hematopoietic markers [14,15]. Until now, the best way to distinguish MSCs from fibroblasts is based on the analysis of the functional properties of these two kinds of cells; MSCs self-renew and retain multipotent differentiation capacity, while fibroblasts seem more limited in both these functional properties [14]. However, a deeper comparative analysis between MSCs and fibroblasts is lacking. In particular, given the importance of

the application of AD-MSCs in cell based therapies, it is relevant to distinguish them from fibroblasts which significantly contribute to the stromal cell population of adipose tissue. In order to fill this gap and to find functional features that may better help to distinguish culture of AD-MSCs from fibroblasts, in the present work we investigated the phenotypic and functional properties of three different preparations of human AD-MSCs and two normal human dermal fibroblast (HNDFs) cell lines side by side. We confirm that HNDFs and AD-MSCs display similar phenotypic and functional features, including the capacity to differentiate into different cell lineages. We here demonstrate for the first time that, while AD-MSCs possess a strong anti-inflammatory and angiogenic potential, HNDFs do not.

Methods

Isolation and culture of human AD-MSCs and Fibroblasts

Human fat specimens were excised from 3 patients after approval by the ethics committee of "MIULLI" General Regional Hospital (Acquaviva, Bari). Informed consent was obtained from each human donor. Adipose tissue samples were collected under sterile conditions from 3 male donors (aged from 40 and 60 years) who underwent standard laparoscopic surgery (uncomplicated colecistectomy and inguinal hernia), after a negative blood screening for HIV, HBV, HCV, Treponema pallidum, HTLV-I and II. Each adipose tissue sample was treated and cultured separately.

Human AD-MSCs were isolated as described [3,15]. Briefly, sterile adipose tissue samples were transferred in 50 ml falcon tubes containing PBS plus penicillin-streptomycin solution and quickly transferred at 4°C temperature to our laboratories. Each sample was repeatedly washed with PBS for blood residual and connective tissue removal. Subsequently, fat specimens were minced with scissors and washed with PBS by centrifugation at 250 × g. After liquid phase removal, collagenase solution (0,25% w/v) (SIGMA St. Louis, Mo, USA) plus 200 µl DNAase (SIGMA) at 1:100 dilution were added to pellets. All tubes were then incubated at 37°C for 2 hours. After enzymatic digestion, cells were washed by centrifugation at 250 × g for 10'. The pellets were resuspended in DMEM +10% FBS medium, filtered (100 µm Ø) to remove undigested tissue, seeded into T 25 culture flasks and incubated at 37°C in a humidified atmosphere containing 5% CO₂. The following day, the medium was aspirated and the adherent AD-MSCs were cultured in EGM medium supplemented with 10% FCS, 50 ng/ml bFGF and antibiotics (Lonza, Verviers, Belgium). The two normal human adult dermal fibroblasts (HNDFs) cell lines were purchased from Lonza (Verviers, Belgium catalogue N° CC25) and cultured under identical conditions used for AD-MSCs. Cultures were routinely passed at

70-80% of confluence and, for this study, cultures were not expanded for more than 8-10 *in vitro* passages. The growth rate of each AD-MSCs preparation and for HNDFs was determined as previously described [15]. Briefly, AD-MSCs and HNDFs (at passage 4) were harvested from the culture flask by treatment with trypsin (Sigma) in PBS (0.05% w/v). Following enzyme inactivation and centrifugation, cells were resuspended in EGM +10% FCS and 50 ng/ml bFGF and seeded at a final density of 2×10^4 cells/ml in T25 culture flasks. After a 7-day incubation, AD-MSCs and HNDFs were detached and counted by hemocytometer.

Characterization of human AD-MSCs and HNDFs

Cultures of AD-MSCs and HNDFs were characterized by flow cytometry (FC). After trypsinization, cells were resuspended with FC buffer (pH 7.2 PBS, BSA 0.5%, Sodium Azide 0.02%) and fixed with paraformaldehyde 2%. AD-MSCs and HNDFs were marked at concentration of $1 \times 10^5/500 \mu\text{l}$. For phenotypic analysis, fluorescein isothiocyanate (FITC-F), phycoerythrin (PE) or phycoerythrin-cyanin PC5 conjugate-antibodies were used. The expression of the following markers were investigated: CD44F, CD90PE, CD34PE, CD45F, CD54F, CD146PE, CD117PC5, CD31F, vWf-F, CD105PE, CD106PE, CD166F, CD40F, CD80F, CD86PE, FAS (CD95 member of the family of TNF α 's receptors), FAS-L (CD178 ligand of FAS) (Immunotech[®], Milan, Italy), CD56PE (Serotec[®], Italy), HLAIF, HLAIPE, CD29PE, CD49dPE (Biolegend[®], Italy), Stro-1PE (R&D[®], Milan, Italy), CD133 (Miltenyi Biotec[®], Bologna, Italy). AD-MSCs and HNDFs were incubated for 20'/room temperature in a dark room and then cells were washed with FC buffer to remove not-conjugated antibodies. Epics "XL-MCL" (Beckman Coulter USA) flow cytometer was used for simultaneous forward (FSC) and side scatter (SSC) measuring, and analyzing the multi-parametric fluorescent phenotypic marker signals. 20,000 events were acquired for each analysis. Sample histogram elaboration was performed with EXPO 32 software to assess fluorescent distribution.

Aldefluor test (Aldagen, Inc., North Carolina, USA) was used to identify, evaluate, and isolate cells with low side scatter which expressed high levels of aldehyde dehydrogenase (ALDH). ALDH cells have been shown to have properties of stem and progenitor cells [16].

The cellular samples were adjusted to a concentration of 1×10^6 cells/ml with Assay Buffer provided in the kit. The adjusted cell suspension was placed into each "test" sample tube.

DEAB (diethylaminobenzaldehyde) solution, provided in the kit, was added to the "control" tube. The samples were incubated for 40' at 37°C in the dark. Following incubation, the tubes were centrifuged for 5' at $250 \times g$. The

pellets were suspended in 0.5 ml of Aldefluor Assay Buffer provided by the kit and analyzed immediately by FC.

Differentiation of AD-MSCs and HNDFs

To examine the capacity of AD-MSCs and HNDFs to differentiate toward adipogenic, osteogenic and cardiomyogenic cell lineages, lineage-specific induction factors were used. For osteogenic differentiation, AD-MSCs and HNDFs were cultured in the presence of DMEM/F-12 supplemented with 10% FBS, 0.1 mM dexamethasone (Sigma), 10 mM β -glycerolphosphate (Sigma) and 50 mM ascorbic acid (Sigma) for around 2 weeks. At the end of incubation, osteogenic differentiation was assessed by alkaline phosphatase (AP) expression (Miltenyi Biotec[®]). Fully differentiated osteoblast-like cells generated from AD-MSCs and HNDFs changed their original fibroblastic shape into a cubical/epithelial shape with prominent cytoplasmic extensions similar to an osteoblast morphology. Cells stained for AP activity with NBT substrate appeared purple in color. Adipogenic differentiation was obtained upon cultivation of AD-MSCs and HNDFs in DMEM supplemented with 10% FBS, 1 mM dexamethasone (Sigma), 0.5 mM methyl-isobutyl-xanthine (Sigma), 10 mg/ml insulin (Invitrogen, Carlsbad, CA) and 100 mM indomethacin (Sigma) for 3 weeks. At the end of incubation, adipogenic-like cells were revealed by staining with Oil Red O (Sigma). Moreover, to confirm adipogenic differentiation, we analyzed the production of Adiponectin by HNDFs and AD-MSCs by FC using anti-Adiponectin antibodies (Sigma). Cardiomyogenic differentiation of AD-MSCs and HNDFs was assessed by immunofluorescent assay by testing the expression of anti-Desmin (Sigma), anti-Troponin C-cardiac (TNP-C), anti-Myocardial actin (MyoA), anti-Connexin 43 (Cx43) and anti-Atrial Natriuretic factor, all purchased from Biodesign International (Saco, ME, USA). Cardiomyogenic markers expression on AD-MSCs and HNDFs was analyzed upon 3 weeks of culture in EGM complete medium in the presence or in the absence of 1 μM 5-azacytidine (Sigma) as previously described [15]. Briefly, after washing, the cells were incubated with secondary antibodies Beckman Coulter FITC-conjugated Goat anti Mouse-IgG (Immunotech[®], Milan, Italy) for 2 hours at room temperature. Then the cells were washed to remove excess antibodies. In order to stain the nuclei, samples were incubated with DAPI (dilution 1:10,000 in PBS, Sigma) for 8' at room temperature. As negative controls, irrelevant isotype-matched antibodies were used. The slides were then mounted in Gel Mount (Biomedica, Foster City, CA) and sealed. Fluorescence analysis was established with fluorescence inverted microscope Leica DM IL (Leica Microsystems GmbH, Wetzlar, Germany). The images were adjusted in contrast and brightness

with the image processing module “Ambient LAS” for the acquisition and overlay of fluorescent images (Leica Microsystems GmbH, Wetzlar, Germany).

Evaluation of Growth factors and cytokines production by AD-MSCs and HNFs

ELISA-tests were performed to detect growth factors and cytokines released by AD-MSCs and HNFs in the culture medium. Aliquots (2 ml) of conditioned medium (CM) from AD-MSCs (AD-MSCs-CM) and HNFs (HNFs-CM) cultures were collected after 72 hours at 70-80% of cell confluence and between 5-8 in vitro passages. Afterwards, AD-MSCs and HNFs were detached with trypsin, counted and stained with Trypan Blue to detect cell viability and to normalize the amount of released factors in respect to the number of cells.

The growth factors, Vascular Endothelial Growth Factor (VEGF α), Transforming Growth Factor β 1 (TGF- β 1), Hepatocyte Growth Factor (HGF), Platelet-derived Growth Factor (PDGF), Angiopoietin 1 (Ang-1) and 2 (Ang-2), IL6 and IL8 production were quantified with ELISA-kits (R&D Systems, UK, Europe), according to the manufacturer’s instructions.

The specific protein concentration in CMs was detected in accordance with the standard guideline protocol supplied with ELISA kit. The background value of each growth factor analyzed and contained in the control medium was subtracted. Absorbance was measured at 450 nm with a microplates photometric reader DV990BV4 (GDV, Italy).

Data were expressed as mean \pm SD of the secreted factor per 10⁶ cells. Assay was repeated twice and each sample was run in triplicate.

Evaluation of Angiogenic potential of AD-MSCs and HNFs

To assess the angiogenic potential of AD-MSCs and HNFs, we investigated the capacity of their CMs on the proliferation of Human Umbilical Vein ECs (HUVECs) (Lonza) and Human derma-derived microvascular ECs (HMECs) isolated as previously described [17]. Both ECs phenotypes were routinely maintained in EGM bullet kit (Lonza) plus 10% FCS. ECs proliferation assay was performed as described [17]. Briefly, HUVECs and HMECs (at passage 3) were harvested from culture flasks by trypsin. After enzyme inactivation and centrifugation, cells were resuspended in EGM medium +0.2% BSA and counted. To evaluate the growth response to AD-MSCs-CM and HNFs-CM, 0.5 ml of HUVECs and HMECs (10⁴ cells) were seeded into each well of a 24-multiwell plate coated with collagen type I; after cell adhesion, medium was aspirated and replaced with EGM complete medium (+10% FCS + 50 ng/ml bFGF) supplemented or not with different dilutions of CM. Positive control

growth medium consisted in EGM complete medium plus 10 ng/ml of VEGF α (Lonza). After 72 h, the wells were washed and the cells were fixed and stained. The cells were counted with a calibrated ocular eyepiece in 10 different fields at 400 \times magnification. Every test was run in triplicate, and at least 3 different CM preparations were tested for both AD-MSCs and HNFs.

To test the effect of AD-MSCs-CM and HNFs-CM on ECs tube formation, we used growth factor reduced-matrigel assay (Sigma) as described by Kleinman et al [18]. Briefly, around 50 μ l of matrigel were seeded into cold (maintained at 4 $^{\circ}$ C) wells of a 96-multiwell plate. After matrigel jellification at 37 $^{\circ}$ C for 30', HUVECs and HMECs were seeded on matrigel at concentration of 10⁴ cells/well in 50 μ l of EGM control growth medium diluted (1:1) or not with AD-MSCs-CM and HNFs-CM. On day 2 and 5 after seeding, the number of EC tube formations were counted at 10 \times magnification by inverted microscopy and reported as n $^{\circ}$ of tube structures/field.

Evaluation of anti-inflammatory activity of AD-MSCs and HNFs

The anti-inflammatory activity of AD-MSCs and HNFs was tested by applying AD-MSCs-CM and HNFs-CM on the U937 monocyte cell line (ATCC Manassas VA, USA), both in the absence and the presence of inflammatory stimuli LPS 1 μ g/ml (Sigma) and TNF α 25 ng/ml (Sigma). The expression of the adhesion molecules CD54, CD44, CD62L and CD49d on U937 were analyzed by FC. Briefly, U937 cells cultured in RPMI (Sigma) +10% FCS were counted and diluted to a concentration of 2 \times 10⁵/ml. In a first series of experiments, U937 were cultured in the presence or absence of different dilutions of AD-MSCs-CM and HNFs-CM for 24 hours. Afterwards, the cells were washed and pulsed with TNF α 25 ng/ml for a further 12 hours. At the end of incubations, U937 were treated, for 20'/room temperature in dark room, with the different adhesion molecules antibodies. After washing cells to remove not-conjugated antibodies, adhesion molecules expression was analyzed by FC. Using a similar procedure, we also evaluated the adhesion molecules expression on AD-MSCs and on HNFs pulsed or not for 12 hours with TNF α 25 ng/ml. ELISA-kits were used to quantify the production of RANTES and MCP-1 (R&D Systems, UK, Europe) by U937 under basal culture conditions, in the presence of inflammatory stimuli (LPS 1 μ g/ml and TNF α 25 ng/ml) and in the presence of AD-MSCs-CM and HNFs-CM. Finally, we also evaluated the effect of AD-MSCs-CM and HNFs-CM on RANTES and MCP-1 release by U937, after priming with TNF α . Briefly, AD-MSCs and HNFs were exposed for 12 hours to TNF α 25 ng/ml. Thereafter, cells were washed and further incubated for 24 hours. At the end of

incubation, their CMs were collected and tested on U937 chemokines production. All the data were normalized for 10^6 cells in 24 hours incubation. and the basal level production of the same chemokines present in the AD-MSCs-CM and in HNDFs-CM was subtracted.

Statistic analysis

Results are expressed as mean \pm standard deviation (SD). Statistical significance was evaluated by analysis of variance followed by Tukey-Kramer multiple comparison test and by Student's t-test. A p value of less than 0.05 denotes statistical significance.

Results

Culture of AD-MSCs and HNDFs showed a very similar morphological appearance and phenotypic profile

AD-MSCs were isolated from subcutaneous fat specimens obtained from 3 patients during the course of abdominal surgery. AD-MSCs were cultured using EGM medium supplemented with 10% FCS and bFGF. Successful isolation and culture expansion of AD-MSCs were obtained from all three specimens processed. HNDF cell lines were maintained *in vitro* under the same culture conditions of AD-MSCs. HNDFs and AD-MSCs proliferated well in culture with an average doubling time of 28-36 hrs and 38-46 hrs respectively. Cells were usually plated in T25 culture flasks at a density of 20,000 cells/cm². Soon after culture, AD-MSCs showed typical fibroblast-like morphology and did not display any particular morphological differences when compared to HNDFs, even upon 10 *in vitro* passages (Additional file 1: Figure S1).

The phenotypic profile of AD-MSCs and HNDFs was determined by FC analysis and was performed upon 5 *in vitro* passages. At first, we analyzed the presence of stem cell markers such as CD34, Stro-1, CD146, CD117, CD133 and ALDH. As reported in Table 1, neither AD-MSCs nor HNDFs expressed the stem cell markers investigated, only ALDH was significantly expressed in approximately 40% of the cells, but again, there was no substantial difference between AD-MSCs and HNDFs (Additional file 2: Figure S2)

In Table 1 all the results on the phenotypic characterization of HNDFs and AD-MSCs regarding mesenchymal, endothelial and immunogenic markers (see also Additional file 3: Figure S3) are summarized. The variation of each marker among the 3 different AD-MSC preparations and the two HNDF cell lines analyzed was less than 10%. Cells were almost 100% positive for CD29, CD90, CD44 and CD105 mesenchymal markers, and were practically negative for EC markers CD31 and vWf. AD-MSCs and HNDFs had a very similar adhesion molecules profile, showing a variable positivity for markers such as CD166, CD54, CD106 and CD56.

Table 1 Phenotypic characterization of human AD-MSCs and HNDFs

	AD-MSCs % of positive cells (\pm SD)	HNDFs % of positive cells (\pm SD)
<i>Stem cell markers</i>		
Stro-1	3.7 \pm 3.2	5.5 \pm 0.4
CD146	1.5 \pm 1.0	1.2 \pm 1.2
CD133	0.4 \pm 0.3	absent
CD34	absent	absent
CD117	0.1 \pm 0.1	absent
ALDH	42 \pm 8.3	41.0 \pm 5.4
<i>Mesenchymal markers</i>		
CD105	98.4 \pm 1.0	95.6 \pm 2.2
CD90	97.6 \pm 2.5	94.1 \pm 3.2
CD44	92.5 \pm 3.6	97.1 \pm 1.1
CD29	95.5 \pm 2.0	91.1 \pm 5.4
<i>AM markers</i>		
CD166	66.1 \pm 26.4	80.4 \pm 5.8
CD106	25.2 \pm 15.1	35.6 \pm 7.8
CD54	19.6 \pm 9.4	25.7 \pm 15.5
CD56	17.8 \pm 12.2	39.6 \pm 5.6*
CD49d	10.8 \pm 3.4	58.9 \pm 22.4**
<i>Endothelial markers</i>		
CD31	absent	absent
vWf	absent	absent
<i>Immunological markers</i>		
CD40	17.7 \pm 5.9	84.1 \pm 3.6**
CD80	4.6 \pm 1.1	2.1 \pm 0.9
CD86	2.6 \pm 1.1	0.8 \pm 0.7
CD45	absent	absent
HLA-II	0.5 \pm 0.5	1.1 \pm 1.2
HLA-I	93.3 \pm 3.3	94.0 \pm 2.8

Table shows the phenotypic characterization of AD-MSCs and HNDFs in culture. FACS analysis was performed when all cultures were at 5 *in vitro* passages. Data represent the % of positive cells for each marker analyzed on AD-MSCs and on HNDF and are means \pm SD. Variability of each marker tested among the different cell preparations were \leq 10%. Note that some markers such as CD56, CD49d and CD40 are more highly expressed in HNDFs when compared to AD-MSCs. *p < 0.05 and **p < 0.01 compared to AD-MSCs.

Interestingly, only CD49d, an integrin involved in the homing of cells to an inflammatory site [19], was significantly more highly expressed on HNDFs compare to AD-MSCs. Finally, the comparative analysis of markers involved in immune response demonstrated again a strong similarity between AD-MSCs and HNDFs. They both expressed very low levels of CD80 and CD86 and they lacked CD45 and HLA-II expression, while HLA-I was present in 100% of the cells. Interestingly CD40, a

co-stimulatory protein found on antigen presenting cells (APCs) [20], was more highly expressed on HNDFs, suggesting a higher immunogenic profile of HNDFs if compared with AD-MSCs. This data further confirms previous results showing the positive expression of CD40 on dermal fibroblasts [21]

AD-MSCs and HNDFs display similar differentiation capacity

A typical feature of MSCs is their multipotential differentiation capacity [2,3]. Previous reports indicate that MSCs of different tissue origin have the capacity to differentiate into different cell lineages, while the multipotential differentiation capacity of fibroblasts is more controversial [14]. Therefore, we compared the capacity of AD-MSCs and HNDFs to differentiate into different cell lineages. Under the same differentiation culture conditions, AD-MSCs and HNDFs were

induced to differentiate into osteogenic, adipogenic and cardiomyocyte-like cells. As shown in Figure 1, AD-MSCs and HNDFs differentiate well into osteoblast-like and into adipocyte-like cells assessed by the positivity to AP and Oil Red O staining respectively (Figure 1A). To further confirm adipogenic differentiation, AD-MSCs and HNDFs were also analyzed for Adiponectin expression, a hormone specifically produced by mature adipocyte [22]. Upon adipogenic differentiation, we found a similar significant increment of Adiponectin expression in both AD-MSCs and HNDFs (Additional file 4: Figure S4). They both differentiated into cardiomyocyte-like cells, although a more intense staining of MyoA, TNP-C and Desmin on AD-MSCs was observed (Figure 1B). Other myocardial markers, such as Cx43 and atrial natriuretic factor, were not detected on either HNDFs or AD-MSCs (data not shown).




Figure 1 AD-MSCs and HNDFs display similar capacity to differentiate into adipogenic, osteogenic and cardiomyogenic cell lineages. The Figure shows the capacity of AD-MSCs and HNDFs to differentiate toward the adipogenic, osteogenic and cardiomyogenic cell lineages in the presence of lineage-specific induction factors. In (A) is shown the positive staining of AD-MSCs and HNDFs for Oil Red O and AP, indicating differentiation into adipogenic and osteogenic cell lineages respectively (magnification 20x). In (B) note the positive immunofluorescence staining of AD-MSCs and HNDFs for Desmin, MyoA and TNP-C cardiomyogenic markers (magnification 10x).

AD-MSCs, but not HNDFs, possess strong angiogenic potential *in vitro*

To define the angiogenic activity of AD-MSCs and HNDFs, we first analyzed the production of angiogenic growth factors and cytokines in their CM. AD-MSCs and HNDFs were cultured for 72 hours, CM was then analyzed by ELISA for the presence of VEGFa, HGF, TGF β 1, Ang-1, Ang-2 and PDGF. AD-MSCs demonstrated a great capacity to produce a broad spectrum of angiogenic factors (Figure 2). In 72 hours of culture, 10⁶ cells produced an extremely high level of the angiogenic factors HGF and VEGFa. AD-MSCs produced also significant amounts of TGF β 1, Ang-1 and Ang-2 and, to a minor extent, PDGF. Interestingly, HNDFs had a significantly lower production of all the angiogenic factors analyzed. Compared to AD-MSCs, VEGF, HGF and Ang-1 production in HNDFs was significantly lower.

We also analyzed the production of angiogenic cytokines, such as IL6 and IL8, which were produced in good quantities by both kinds of mesenchymal cells (Additional file 5: Figure S5).

The angiogenic capacity of AD-MSCs and HNDFs was also evaluated on the proliferation of HUVECs and HMECs. As shown in Figure 3, the addition of AD-MSCs-CM, at all different dilutions tested, enhanced growth of both HUVECs (Figure 3A) and HMECs (Figure 3B). In contrast, the addition of different dilutions of HNDFs-CM did not enhance the proliferation of either HUVECs (Figure 3A) or HMECs (Figure 3B). The capacity AD-MSCs and HNDFs to stimulate angiogenesis was also tested *in vitro* by evaluating the formation of capillary-like structures on matrigel. AD-MSCs-CM and HNDFs-CM were added to HMECs cultured on matrigel, a matrix that induces




Figure 2 AD-MSCs, but not HNDFs, produce high levels of angiogenic factors. ELISA-tests were performed to detect VEGFa, TGF- β 1, HGF, PDGF, Ang-1 and Ang-2 angiogenic factors released by AD-MSCs and HNDFs in the CM. Note that AD-MSCs, compared to HNDFs, release very high quantities of VEGFa, HGF and Ang-1. Data are the absolute values expressed as mean \pm SD of the secreted factor per 10⁶ cells after 72 hrs of incubation. The background values of angiogenic factors contained in EGM control medium (supplemented with 10% FCS and 50 ng/ml bFGF) were subtracted. Tests were run in triplicate and repeated twice. ** p < 0.01 versus HNDFs release.




Figure 3 AD-MSC-CM possess a higher capacity to stimulate HUVECs and HMECs proliferation and tube formations compared to HNFDFs-CM. The effect of AD-MSCs-CM and HNFDFs-CM on proliferation of HUVECs (A) and HMECs (B) was tested by adding different dilutions to EGM control medium. As a positive growth control, we used VEGFa 10 ng/ml. AD-MSCs-CM addition had a great capacity to stimulate the proliferation of HMECs (B) and to a minor extent HUVECs (A), while HNFDFs-CM addition did not affect ECs proliferation at any dilution tested. In (C) and in (D) are shown the capacity of AD-MSCs-CM and HNFDFs-CM to induce HMECs tube formation respectively. AD-MSCs-CM and HNFDFs-CM were added at a ratio 1:1 with EGM control medium (Magnification 10x). Note that AD-MSCs-CM not only increased HMECs tube formation on day 2, but also delayed their regression on day 5. The columns in (A) and (B) are mean \pm SD of three independent experiments run in triplicate. * $p < 0.05$ and ** $p < 0.01$ versus CTRL.


capillary-like structure formation that usually regresses within 3-4 days of culture [18]. As shown in Figure 3C and 3D, within 2 days, the presence of AD-MSCs-CM in the control medium substantially triplicated (AD-MSCs-CM 25 ± 17 versus HNFDFs-CM 8 ± 6) the number of HMECs tube formations. Moreover, compared to HNFDFs-CM, AD-MSCs-CM produced a significant delay of capillary-like structures regression (Figure 3C and 3D). The effect of AD-MSCs-CM on HUVECs was similar (data not shown).

AD-MSCs, but not HNFDFs, possess strong anti-inflammatory activity in vitro

It has been shown that MSCs display anti-inflammatory capacity [15,23,24]. We thus investigated whether AD-MSCs and HNFDFs may produce molecules with anti-inflammatory activity by testing their CM on U937, a human monocyte cell line, under basal culture conditions or in the presence of TNF α inflammatory stimuli. As shown in Figure 4, the expression of the adhesion

molecules CD54, CD44, CD62L, CD49d on U937 was not significantly affected by the addition of both AD-MSCs-CM and HNFDFs-CM to the basal control medium. After stimulation of U937 with TNF α (25 ng/ml), expression of CD54 (Figure 4A), CD44 (Figure 4B) and CD62L (Figure 4C) was increased and the addition of AD-MSCs-CM (at 1:1 dilution) was able to antagonize the increment (Figure 4A, B and 4C). In contrast, the addition of HNFDFs-CM did not affect adhesion molecules increment induced by TNF α ; only CD54 expression was slightly reduced (Figure 4A). Neither AD-MSCs-CM nor HNFDFs-CM had any effect on CD49d expression (Figure 4D).


We also investigated the effect of AD-MSCs-CM and HNFDFs-CM on CD11a and CD11b expression, adhesion molecules that are involved in inflammatory cells migration [25]. Only AD-MSCs-CM, but not HNFDFs-CM, induced a slight decrement of CD11a and CD11b expression on U937 (Additional file 6: Figure S6). We next investigated the capacity of AD-MSCs-CM and HNFDFs-CM to affect the release of RANTES and MCP-1 inflammatory chemokines by U937, under basal culture conditions or in the presence of TNF α and LPS stimuli. AD-MSCs and HNFDFs, per se, released very little amounts of both RANTES and MCP-1 (< 20 pg/ml for each chemokine) (data not shown). However, as shown in Figure 5, the addition of AD-MSCs-CM to U937 culture greatly inhibited RANTES (Figure 5A) and MCP-1 (Figure 5B) release in a dose dependent manner either in the presence or absence of LPS (1 μ g/ml) inflammatory stimulation. By contrast, however, the addition of HNFDFs-CM at every dilution tested did not (Figure 5A and 5B). The capacity of AD-MSCs-CM to block RANTES and MCP-1 chemokines release was even more potent if U937 was stimulated with TNF α for 12 hours (Figure 5C and 5D). Finally, we asked whether exposing AD-MSCs and HNFDFs to the inflammatory cytokine TNF α may induce changes in their activity on U937 chemokines release. To this end, AD-MSCs and HNFDFs were primed for 12 hours with TNF α (25 ng/ml), thereafter the medium was replaced with fresh medium, and 24 hours later CM was recovered and tested on U937 chemokines production. As shown in Figure 6, TNF α primed-AD-MSCs-CM (P-AD-MSCs-CM) added to U937 enhanced inhibition of RANTES and MCP-1 release by U937, either in the presence or absence of TNF α stimuli. Thus, priming with TNF α improved anti-inflammatory activity of AD-MSCs on U937 chemokines release. Interestingly, the addition of TNF α primed-HNFDFs-CM (P-HNFDFs-CM) produced, by contrast, a significant increment of chemokines release by U937 (Figure 6), indicating that HNFDFs, under stimulation with TNF α , behave in an opposite manner.



Discussion


Among the different stem cell phenotypes, adult MSCs represent an extremely valid cell option to apply to regenerative therapies. Besides their capacity to differentiate into many different cell lineages, including neural cells [26], MSCs display immunosuppressive [27], anti-inflammatory [15,23], anti-apoptotic [28] and angiogenic activity [15,28]-all distinguishing features of cells with potential regenerative properties [29]. In addition, MSCs can be isolated from many different adult human tissues [2-7]; in particular, BM and adipose tissue are sufficiently rich in MSCs content. For this reason, MSCs derived from BM and adipose tissue have been investigated more deeply and have been found to show similarities in terms of phenotypic profile, differentiation potential and *in vivo* regenerative capacity [7].

Procedures for their extraction and culture expansion have been fully described [2,3]. However, one of the major unsolved problems is the purity of MSCs preparation to use for therapeutic purposes. In fact, because of a lack of specific MSC markers, the presence of contaminating mature stromal cells, such as fibroblasts, cannot be distinguished and quantified, particularly in a fresh preparation or even in an expanded culture of AD-MSCs. Data from Lennon et al indicate that human BM-MSCs intentionally contaminated by dermal fibroblasts continue to elicit a positive osteochondrogenesis both *in vitro* and *in vivo* [30]. However, since there are very few comparative studies between AD-MSCs and fibroblasts and because the grade of purity of AD-MSC preparations may directly affect their *in vivo* efficacy [31,32], in the present study, we asked whether



AD-MSCs are unique or whether they may share essential characteristics with fibroblasts. To this end, we compared the phenotypic and functional features of AD-MSCs and two dermal fibroblast cell lines. AD-MSCs were prepared from three different human donors following a standard procedure [15]. In contrast, we decided to use two commercial established fibroblast cell lines, to reduce the presence of cross-contaminating MSCs-like cells which could be present in fresh culture of dermal fibroblasts [10]. Moreover, commercial cell lines, are usually well characterized and composed of a more homogenous cell population if compared to fresh cell preparations. In fact, FC analysis of the two HNF cell lines used confirmed the high level of stromal cell purity; cells were almost 100% positive for each mesenchymal marker tested (Table 1). In this regard, the analysis of the phenotypic profile confirms previous

publications that indicate the absence of distinguishing markers in AD-MSCs and HNFs [10,14]; they both expressed typical MSCs markers, were negative for endothelial and hematopoietic markers and even similarly negative for many stem cell markers, in particular Stro-1 and CD146, which are, by contrast, described on BM-MSCs [11,13]. Only ALDH activity, a stemness functional marker used for identification of stem cells and progenitors [16], was similarly present on both AD-MSCs and HNFs. In this study, we also investigated the presence of immunogenic cell surface molecules on AD-MSCs and HNFs. We found that CD54, CD80 and CD86 were similarly expressed, by contrast, CD40, a co-stimulatory protein found on APCs [20], was more highly expressed only on HNFs. These data suggest that mature fibroblasts could have a higher immunogenic profile than AD-MSCs. In fact, the presence of



very low levels of CD40 combined with the absence of CD14 and HLA-DR may not be sufficient to endow AD-MSC with APC function. In this study, we did not investigate the immunosuppressive activity of AD-MSCs and HNDFs, because publications have already well described the immunosuppressive activity of both fibroblasts and MSCs [27,33].

We could not find any differences between AD-MSCs and HNDFs regarding morphological appearance in culture, growth rate and, more interestingly, in multipotential differentiation capacity. Hence our results are in contrast with Wagner et al [14] but support the finding of Lorenz et al who propose dermal fibroblasts for application in the therapy of wound healing because of their multilineage differentiation potential [10].

Besides this aspect, in our opinion this study has disclosed important new insights into functional differences between AD-MSCs and HNDFs. More specifically, it is known that HNDFs play an important role in angiogenesis, providing the extracellular matrix molecules

necessary to support capillary morphogenesis [34] and a balance of pro-angiogenic and anti-angiogenic factors to determine the final vascular density [35,36]. We did not investigate the production of extracellular matrix proteins produced by AD-MSCs and HNDFs in culture, but instead, we studied both the content of angiogenic growth factors, such as VEGFa, HGF, TGF β 1, Ang-1 and Ang-2 and PDGF released in the CM and, concomitantly, their activity on ECs proliferation and tube-like formations. We demonstrated, for the first time, that AD-MSCs were extremely more angiogenic than HNDFs. Indeed, if compared to HNDFs-CM, the level, in particular of VEGFa, HGF and Ang-1, was significantly higher in the AD-MSCs-CM as was its capacity to stimulate ECs proliferation. This data is consistent with our [15] and other previous reports [29] indicating the strong angiogenic potential of AD-MSCs and their potential use for the therapy of ischemic diseases [15,29]. Vice-versa, HNDFs appear less angiogenic. Although it is still under debate, if fibroblasts can be considered more mature cells than

MSCs, our data may indicate that the angiogenic potential of MSCs could be inversely related with their grade of maturation, explaining, at least in part, the reason why dermal fibroblasts are less efficient than MSCs in promoting wound healing [37]. In addition AD-MSCs, but not HNDFs, were able to improve and stabilize HMECs tube-like formation, probably through their capacity to secrete significant quantities of Ang-1, an angiogenic factor involved in vascular morphogenesis [38]. This result expands on previous observations proposing that MSCs are different from fibroblasts and more similar to pericytes, [39] also because MSCs and pericytes are located in the wall of vasculature [6,40].

This study confirms the strong anti-inflammatory potential of AD-MSCs [15,23] and concomitantly highlights, for the first time, that HNDFs lack this property. In our opinion, this appears to be the most distinguishing feature between AD-MSCs and HNDFs. AD-MSCs were able to reduce adhesion molecules expression and inhibit the U937 release of the inflammatory chemokines RANTES and MCP-1, under different inflammatory stimuli. HNDFs did not affect any of the inflammatory activities of U937 monocytes. More interestingly, our results disclose a little-studied characteristic of AD-MSCs and HNDFs. Indeed, we observed that, under inflammatory stimuli, AD-MSCs and HNDFs behave in an opposite manner on U937 chemokines release. Upon priming with TNF α , AD-MSCs increased their capacity to block the release of RANTES and MCP-1, while HNDFs, by contrast, acquired pro-inflammatory activity, enhancing chemokines release by U937. To our knowledge, this is a new finding, that could be used not only to clearly distinguish between AD-MSCs and fibroblasts preparations, but also to improve MSCs regenerative properties when applied to cell therapy of ischemic diseases [41]. In addition, enhancing anti-inflammatory activity of MSCs may provide a better strategy to affect diseases where inflammation plays an important role in supporting progression.

Conclusions

This study shows evidence that AD-MSCs and HNDFs share a number of similar phenotypic functional features, including the capacity to differentiate into different cell lineages. We demonstrate that, to distinguish AD-MSCs and HNDFs cultures, it is necessary to evaluate their angiogenic and, overall, their anti-inflammatory potential. AD-MSCs are significantly more angiogenic and anti-inflammatory than HNDFs. In addition, under stimulation with TNF α , AD-MSCs and HNDFs behave in an opposite manner: AD-MSCs improve anti-inflammatory activity, while HNDFs enhance inflammation. All together these data suggest that, before application in cell-based therapy, preparations of MSCs require testing for their angiogenic and anti-inflammatory capacity.

Priming them with inflammatory cytokines may be useful for improving their therapeutic efficacy.

Additional material

Additional file 1: Figure S1 Morphological appearance of AD-MSCs and HNDFs in culture. The Figure shows the culture of AD-MSCs and HNDFs at early (P3) and at late (P10) *in vitro* passages. Note that AD-MSCs as well as HNDFs have a similar fibroblastic-like morphology (magnification 10 \times)

Additional file 2: Figure S2 AD-MSCs and HNDFs show a similar ALDH expression. Aldefluor test was used to identify stem and progenitor cells with low side scatter that expressed high levels of ALDH. The Figure shows FC analysis of ALDH expression on both AD-MSCs and HNDFs. Note that both kinds of cell culture contained a similar percentage of ALDH positive cells.

Additional file 3: Figure S3 Marker's expression of AD-MSCs and HNDFs. Note the high expression of mesenchymal markers CD90, CD44, CD105, CD73 and CD166 on both AD-MSCs and HNDF, whereas HNDFs expressed higher levels of CD40 and CD49d.

Additional file 4: Figure S4 AD-MSCs and HNDFs produce high level of Adiponectin after adipogenic differentiation. Adiponectin expression was used to confirm adipogenic differentiation of AD-MSCs and HNDFs. The figure shows the FC of Adiponectin expression before and after adipogenic differentiation of AD-MSCs and HNDFs. Note that both kinds of cell culture expressed high level of Adiponectin after differentiation.

Additional file 5: Figure S5 AD-MSCs, and HNDFs, produce high levels of IL6 and IL8. ELISA-tests were performed to detect IL6 and IL8 cytokines released by AD-MSCs and HNDFs in the CM. Note that both AD-MSCs, and HNDFs, release a high quantity of IL6 and IL8. Data are expressed as mean \pm SD of the secreted factor per 10⁶ cells after 72 hrs of incubation. Tests were run in triplicate and repeated twice. The background values contained in EGM control medium were subtracted

Additional file 6: Figure S6 AD-MSCs-CM, but not HNDFs-CM, reduced expression of CD11a and CD11b on U937 monocytes. Note that the addition of AD-MSCs-CM (1:1), but not HNDFs-CM, to U937 culture medium slightly reduced MFI of CD11a CD11b, particularly upon stimulation with TNF α .

List of abbreviations used

AD-MSCs: Adipose-derived MSCs; **AD-MSCs-CM:** conditioned medium-derived AD-MSCs; **ALDH:** aldehyde dehydrogenase; **Ang-1:** Angiotensin-1; **Ang-2:** Angiotensin-2; **AP:** Alkaline phosphatase; **APCs:** antigen presenting cells; **BM:** bone marrow; **BM-MSC s:** bone marrow derived MSCs; **CM:** conditioned medium; **Cx43:** Connexin 43; **ECs:** endothelial cells; **FC:** Flow cytometry; **HGF:** Hepatocyte growth factor; **HNDFs:** Human normal dermal fibroblasts; **HNDFs-CM:** conditioned medium-derived HNDF; **HMECs:** human microvascular endothelial cells; **HUVECs:** human umbilical vein endothelial cells; **MSCs:** mesenchymal stem cells; **MyoA:** myocardial actin; **LPS:** lipopolysaccharide; **P-AD-MSCs-CM:** priming-derived AD-MSCs-CM; **PDGF:** platelet derived growth factor; **P-HNDFs-CM:** priming-derived HNDFs-CM; **SMCs:** smooth muscle cells; **TGF β 1:** transforming growth factor β 1; **TNF α :** tumor necrosis factor α ; **TNP-C:** cardiac troponin; **VEGF:** vascular endothelial growth factor; **vWf:** von Willebrand factor

Acknowledgements

We thank Dr Andrea Smith for checking the English of the manuscript. This research was partially supported by Medestea Research Laboratories and AIRC (Associazione Italiana per la Ricerca sul Cancro) Project AIRC IG-9062 "Role of human mesenchymal stem cells in tumor angiogenesis".

Author details

¹Medestea Research and Production Laboratories, Consorzio Carso, 70010 Valenzano, Bari, Italy. ²Cellular Neurobiology Laboratory, Department of

Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute "Carlo Besta", 20133 Milan, Italy.

Authors' contributions

All authors have read and approved the final manuscript. AB, CM designed experiments, differentiation experiments, performed *in vitro* experiments on U937, performed FACS analysis and ELISA assay. LB, MS Isolation and culture AD-MSCs, immunofluorescent characterization. SEN, LC, SC, and GI Performed experiments on ECs and Matrigel assay, isolation and culture of HUVECs and HMECs, AS, EAP supervised the manuscript, GA conceived, directed the study, and wrote the manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 6 August 2010 Accepted: 8 February 2011

Published: 8 February 2011

References

- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: **Multilineage potential of adult human mesenchymal stem cells.** *Science* 1999, **284**:143-147.
- Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM: **Pluripotency of mesenchymal stem cells derived from adult marrow.** *Nature* 2002, **418**:D42-D49.
- Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH: **Human adipose tissue is a source of multipotent stem cells.** *Mol Biol Cell* 2002, **13**:4279-4295.
- Hu Y, Liao L, Wang Q, Ma L, Ma G, Jiang X, Zhao RC: **Isolation and identification of mesenchymal stem cells from human fetal pancreas.** *J Lab Clin Med* 2003, **141**:342-349.
- Nakatsuka R, Nozaki T, Uemura Y, Matsuoka Y, Sasaki Y, Shinohara M, Ohura K, Sonoda Y: **5-Aza-2'-deoxycytidine treatment induces skeletal myogenic differentiation of mouse dental pulp stem cells.** *Arch Oral Biol* 2010, **55**:350-357.
- Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM, Badyrak S, Bhurinj HJ, Giacobino JP, Lazzari L, Huard J, Péault B: **A perivascular origin for mesenchymal stem cells in multiple human organs.** *Cell Stem Cell* 2008, **3**:301-313.
- Yoshimura H, Muneta T, Nimura A, Yokoyama A, Koga H, Sekiya I: **Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, periosteum, adipose tissue, and muscle.** *Cell Tissue Res* 2007, **327**:449-462.
- Boquest AC, Shahdadfar A, Brinckmann JE, Collas P: **Isolation of stromal stem cells from human adipose tissue.** *Methods Mol Biol* 2006, **325**:35-46.
- Linge C, Green MR, Brooks RF: **A method for removal of fibroblasts from human tissue culture system.** *Exp Cell Res* 1989, **185**:519-528.
- Lorenz K, Sicker M, Schmelzer E, Ruf T, Salvetter J, Schulz-Siegmund M, Bader A: **Multilineage differentiation potential of human dermal skin-derived fibroblasts.** *Exp Dermatol* 2008, **17**:925-932.
- Gronthos S, Graves SE, Ohta S, Simmons PJ: **The STRO-1+ fraction of adult human bone marrow contains the osteogenic precursors.** *Blood* 1994, **84**:4164-4173.
- Bruno S, Bussolati B, Grange C, Collino F, di Cantogno LV, Herrera MB, Biancone L, Tetta C, Segoloni G, Camussi G: **Isolation and characterization of resident mesenchymal stem cells in human glomeruli.** *Stem Cells Dev* 2009, **18**:867-880.
- Sorrentino A, Ferracin M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M, Fatica A, Negrini M, Peschle C, Valtieri M: **Isolation and characterization of CD146+ multipotent mesenchymal stromal cells.** *Exp Hematol* 2008, **36**:1035-1046.
- Wagner W, Wein F, Seckinger A: **Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood.** *Exp Hematol* 2005, **33**:1402-1416.
- De Siena R, Balducci L, Blasi A, Montanaro MG, Saldarelli M, Saponaro V, Martino C, Logrieco G, Soleti A, Fiobellot S, Madeddu P, Rossi G, Ribatti D, Crovace A, Cristini S, Invernici G, Parati EA, Alessandri G: **Omentum-derived stromal cells improve myocardial regeneration in pig post-infarcted heart through a potent paracrine mechanism.** *Exp Cell Res* 2010, **316**:1804-1815.
- Moreb JS: **Aldehyde dehydrogenase as a marker for stem cells.** *Curr Stem Cell Res Ther* 2008, **3**:237-246.
- Alessandri G, Chirivi RG, Fiorentini S, Dossi R, Bonardelli S, Giulini SM, Zanetta G, Landoni F, Graziotti PP, Turano A, Caruso A, Zardi L, Giavazzi R, Bani MR: **Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells.** *Clin Exp Metastasis* 1999, **17**:655-662.
- Kleinman HK, Martin GR: **Matrigel: basement membrane matrix with biological activity.** *Semin Cancer Biol* 2005, **15**:378-386.
- Steinger C, Brenig F, Baumgartner L, Schmidt J, Schmidt A, Bloch W: **Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells.** *J Mol Cell Cardiol* 2008, **44**:1072-1084.
- Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ: **Molecular mechanism and function of CD40/CD40L engagement in the immune system.** *Immunol Rev* 2009, **229**:152-172.
- Fries KM, Sempowski GD, Gaspari AA, Blieden T, Looney RJ, Phipps RP: **CD40 expression by human fibroblasts.** *Clin Immunol Immunopathol* 1995, **77**:42-51.
- Ukkola O, Santaniemi M: **Adiponectin: a link between excess adiposity and associated comorbidities?** *J Mol Med* 2002, **80**:696-702.
- Tanaka F, Tominaga K, Ochi M, Tanigawa T, Watanabe T, Fujiwara Y, Ohta K, Oshitani N, Higuchi K, Arakawa T: **Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitis via anti-inflammatory action in damaged tissue in rats.** *Life Sci* 2008, **83**:771-779.
- Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, Sensebé L, Zhang Y, Gorin NC, Thierry D, Fouillard L: **Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells.** *Gene Expr* 2007, **13**:217-226.
- Paulsson JM, Dadfar E, Held C, Jacobson SH, Lundahl J: **In vivo transmigrated monocytes from patients with stable coronary artery disease have a reduced expression of CD11b.** *Clin Exp Immunol* 2008, **153**:196-204.
- Jiang J, Lv Z, Gu Y, Li J, Xu L, Xu W, Lu J, Xu J: **Adult rat mesenchymal stem cells differentiate into neuronal-like phenotype and express a variety of neuro-regulatory molecules in vitro.** *Neurosci Res* 2010, **66**:46-52.
- Nasef A, Mathieu N, Chapel A, Frick J, François S, Mazurier C, Boutarfa A, Bouchet S, Gorin NC, Thierry D, Fouillard L: **Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G.** *Transplantation* 2007, **84**:231-237.
- Park KS, Kim YS, Kim JH, Choi B, Kim SH, Tan AH, Lee MS, Lee MK, Kwon CH, Joh JW, Kim SJ, Kim KW: **Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation.** *Transplantation* 2010, **89**:509-517.
- Caplan AI: **Why are MSCs therapeutic? New data: new insight.** *J Pathol* 2009, **217**:318-324.
- Lennon DP, Haynesworth SE, Arm DM, Baber MA, Caplan AI: **Dilution of human mesenchymal stem cells with dermal fibroblasts and the effects on in vitro and in vivo osteochondrogenesis.** *Dev Dyn* 2000, **219**:50-62.
- Mosna F, Sensebé L, Krampera M: **Human Bone-Marrow And Adipose Tissue Mesenchymal Stem Cells: A User's Guide.** *Stem Cells Dev* 2010, **19**:1449-1470.
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D: **Minimal criteria for defining multipotent mesenchymal stromal cells.** *Cytotherapy* 2006, **8**:315-317.
- Sarkhosh K, Tredget EE, Karami A, Uludag H, Washina T, Kilani RT, Ghahary A: **Immune cell proliferation is suppressed by the interferon-gamma-induced indoleamine 2,3-dioxygenase expression of fibroblasts populated in collagen gel (FPCG).** *J Cell Biochem* 2003, **90**:206-217.
- Berthod F, Germain L, Tremblay N, Auger FA: **Extracellular matrix deposition by fibroblasts is necessary to promote capillary-like tube formation in vitro.** *Cell Physiol* 2006, **207**:491-498.
- Black AF, Berthod F, L'heureux N, Germain L, Auger FA: **In vitro reconstruction of a human capillary-like network in a tissue-engineered skin equivalent.** *FASEB J* 1998, **12**:1331-1340.
- Hudon V, Berthod F, Black AF, Damour O, Germain L, Auger FA: **A tissue-engineered endothelialized dermis to study the modulation of**

- angiogenic and angiostatic molecules on capillary-like tube formation in vitro. *Br J Dermatol* 2003, **148**:1094-1104.
37. Wu Y, Wang J, Scott PG, Tredget EE: **Bone marrow-derived stem cells in wound healing: a review.** *Wound Repair Regen* 2008, **16**:582.
 38. Thomas M, Augustin HG: **The role of the Angiopoietins in vascular morphogenesis.** *Angiogenesis* 2009, **12**:125-37.
 39. Caplan AI: **All MSCs are pericytes?** *Cell Stem Cell* 2008, **3**:229-230.
 40. Covas DT, Panepucci RA, Fontes AM, Silva WA Jr, Orellana MD, Freitas MC, Neder L, Santos AR, Peres LC, Jamur MC, Zago MA: **Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts.** *Exp Hematol* 2008, **36**:642-654.
 41. Kim YS, Park HJ, Hong MH, kang PM, Morgan JP, Jeong MH, Cho JG, Park JC, Ahn Y: **TNF-alfa enhances engraftment of mesenchymal stem cells into infarcted myocardium.** *Front Biosci* 2009, **14**:2845-2856.

doi:10.1186/2045-824X-3-5

Cite this article as: Blasi et al.: Dermal fibroblasts display similar phenotypic and differentiation capacity to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic potential. *Vascular Cell* 2011 **3**:5.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

